Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results - Image 1

£107.78

Springer Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results

Name: Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results
Brand: Springer
Price: 107.78 GBP
Availability: InStock

Cardiovascular

It has never been this cheap. We have no record of a lower price.

£108 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 89 days • 89 data points

Historical

Generating forecast...

Price Distribution

Price distribution over 89 days • 3 price levels

Days at Price

Current Price

Price Analysis

Most common price: £110 (70 days, 78.7%)

Price range: £108 - £112

Price levels: 3 different prices over 89 days

Description

Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs. From the Back Cover Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs.

Product Specifications

Brand: Springer
Format: paperback
ASIN: 940178048X
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Cardiovascular
Domain: Amazon UK
Release Date: 21 November 2014
Listed Since: 21 November 2014

Barcode

No barcode data available

Springer Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Farnesyltransferase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development)

Increasing the Therapeutic Ratio of Radiotherapy (Cancer Drug Discovery and Development)

Decision Tools for Radiation Oncology: Prognosis, Treatment Response and Toxicity (Medical Radiology)

Radiation Toxicity: A Practical Medical Guide: 128 (Cancer Treatment and Research, 128)

Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances: 42 (Cancer Treatment and Research, 42)

COX-2 Blockade in Cancer Prevention and Therapy (Cancer Drug Discovery and Development)

Rectal Cancer: International Perspectives on Multimodality Management (Current Clinical Oncology)

Organ Directed Toxicities of Anticancer Drugs: Proceedings of the First International Symposium on the Organ Directed Toxicities of the Anticancer ... 4–6, 1987: 53 (Developments in Oncology, 53)

Molecular Targets and Strategies in Cancer Prevention

The Epothilones: An Outstanding Family of Anti-Tumor Agents: From Soil to the Clinic: 90 (Fortschritte der Chemie organischer Naturstoffe Progress in the Chemistry of Organic Natural Products, 90)

Modification of Radiation Response: Cytokines, Growth Factors and Other Biological Targets (Medical Radiology / Diagnostic Imaging)

Nutraceuticals and Cancer

Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy

Death Receptors in Cancer Therapy (Cancer Drug Discovery and Development)

Modern Dermatologic Radiation Therapy

Strategies to Enhance the Therapeutic Ratio of Radiation as a Cancer Treatment

Colorectal Cancer: Prevention, Diagnosis and Treatment

Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)

Molecular Determinants of Radiation Response (Current Cancer Research)

Endocrine Therapies in Breast and Prostate Cancer: 39 (Cancer Treatment and Research, 39)

Retinoids in Oncology (ESO Monographs)

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance: 1 (Resistance to Targeted Anti-Cancer Therapeutics, 1)

Anticarcinogenesis and Radiation Protection 2

Metronomic Chemotherapy: Pharmacology and Clinical Applications